Cargando…

Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status

BACKGROUND: Tumor sidedness as a prognostic factor in advanced stage colon cancer (CC) is well established. The impact of tumor sidedness on the clinical outcomes of stage II and III CC has not been well studied. METHODS: The National Cancer Database (NCDB) was utilized to identify patients with pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Akce, Mehmet, Zakka, Katerina, Jiang, Renjian, Williamson, Shayla, Alese, Olatunji B., Shaib, Walid L., Wu, Christina, Behera, Madhusmita, El-Rayes, Bassel F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042136/
https://www.ncbi.nlm.nih.gov/pubmed/33859934
http://dx.doi.org/10.3389/fonc.2021.592351
_version_ 1783678063993683968
author Akce, Mehmet
Zakka, Katerina
Jiang, Renjian
Williamson, Shayla
Alese, Olatunji B.
Shaib, Walid L.
Wu, Christina
Behera, Madhusmita
El-Rayes, Bassel F.
author_facet Akce, Mehmet
Zakka, Katerina
Jiang, Renjian
Williamson, Shayla
Alese, Olatunji B.
Shaib, Walid L.
Wu, Christina
Behera, Madhusmita
El-Rayes, Bassel F.
author_sort Akce, Mehmet
collection PubMed
description BACKGROUND: Tumor sidedness as a prognostic factor in advanced stage colon cancer (CC) is well established. The impact of tumor sidedness on the clinical outcomes of stage II and III CC has not been well studied. METHODS: The National Cancer Database (NCDB) was utilized to identify patients with pathological stage II and III primary adenocarcinoma of the colon from 2010 to 2015 using ICD-O-3 morphology and topography codes: 8140-47, 8210-11, 8220-21, 8260-63, 8480-81, 8490 and C18.0, 18.2,18.3, 18.5,18.6, 18.7. Univariate (UVA) and multivariable (MVA) survival analyses and Kaplan–Meier Curves with Log-rank test were utilized to compare overall survival (OS) based on tumor location and treatment received. RESULTS: A total of 35,071 patients with stage II (n = 17,629) and III (n = 17,442) CC were identified. 51.3% female; 81.5% Caucasian; median age 66 (range, 18–90). Majority of stage II and III tumors were right sided, 61.2% (n = 10,794) and 56.0% (n = 9,763). Microsatellite instability high (MSI-H) was more common in stage II compared to III, 23.3% (n = 4,115) vs 18.2% (n = 3,171) (p < 0.0001). In stage II MSI-H CC right was more common than left, 78.3% (n = 3223) vs 21.7% (n = 892). There was no significant difference in survival between stage II MSI-H left vs right (5-year OS 76.2 vs 74.7%, p = 0.1578). Stage II MSS CC right was more common than left, 56.0% (n = 7571) vs 44.0% (n = 5943), and survival was better in the left vs right (5-year OS 73.2 vs 70.8%, p = 0.0029). Stage III MSI-H CC was more common in the right than in the left, 75.6% (n = 2,397) vs 24.4% (n = 774) and survival was better in the left (5-year OS 62.5 vs 56.5%, p = 0.0026). Stage III MSS CC was more common in the right than in the left, 51.6% (n = 7,366) vs 48.4% (n = 6,905), and survival was better in the left vs right (5-year OS 67.0 vs 54.4%, p < 0.001). CONCLUSION: Survival was better in left sided tumors compared to right in stage II MSS, stage III MSS, and stage III MSI-H CC.
format Online
Article
Text
id pubmed-8042136
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80421362021-04-14 Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status Akce, Mehmet Zakka, Katerina Jiang, Renjian Williamson, Shayla Alese, Olatunji B. Shaib, Walid L. Wu, Christina Behera, Madhusmita El-Rayes, Bassel F. Front Oncol Oncology BACKGROUND: Tumor sidedness as a prognostic factor in advanced stage colon cancer (CC) is well established. The impact of tumor sidedness on the clinical outcomes of stage II and III CC has not been well studied. METHODS: The National Cancer Database (NCDB) was utilized to identify patients with pathological stage II and III primary adenocarcinoma of the colon from 2010 to 2015 using ICD-O-3 morphology and topography codes: 8140-47, 8210-11, 8220-21, 8260-63, 8480-81, 8490 and C18.0, 18.2,18.3, 18.5,18.6, 18.7. Univariate (UVA) and multivariable (MVA) survival analyses and Kaplan–Meier Curves with Log-rank test were utilized to compare overall survival (OS) based on tumor location and treatment received. RESULTS: A total of 35,071 patients with stage II (n = 17,629) and III (n = 17,442) CC were identified. 51.3% female; 81.5% Caucasian; median age 66 (range, 18–90). Majority of stage II and III tumors were right sided, 61.2% (n = 10,794) and 56.0% (n = 9,763). Microsatellite instability high (MSI-H) was more common in stage II compared to III, 23.3% (n = 4,115) vs 18.2% (n = 3,171) (p < 0.0001). In stage II MSI-H CC right was more common than left, 78.3% (n = 3223) vs 21.7% (n = 892). There was no significant difference in survival between stage II MSI-H left vs right (5-year OS 76.2 vs 74.7%, p = 0.1578). Stage II MSS CC right was more common than left, 56.0% (n = 7571) vs 44.0% (n = 5943), and survival was better in the left vs right (5-year OS 73.2 vs 70.8%, p = 0.0029). Stage III MSI-H CC was more common in the right than in the left, 75.6% (n = 2,397) vs 24.4% (n = 774) and survival was better in the left (5-year OS 62.5 vs 56.5%, p = 0.0026). Stage III MSS CC was more common in the right than in the left, 51.6% (n = 7,366) vs 48.4% (n = 6,905), and survival was better in the left vs right (5-year OS 67.0 vs 54.4%, p < 0.001). CONCLUSION: Survival was better in left sided tumors compared to right in stage II MSS, stage III MSS, and stage III MSI-H CC. Frontiers Media S.A. 2021-03-30 /pmc/articles/PMC8042136/ /pubmed/33859934 http://dx.doi.org/10.3389/fonc.2021.592351 Text en Copyright © 2021 Akce, Zakka, Jiang, Williamson, Alese, Shaib, Wu, Behera and El-Rayes https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Akce, Mehmet
Zakka, Katerina
Jiang, Renjian
Williamson, Shayla
Alese, Olatunji B.
Shaib, Walid L.
Wu, Christina
Behera, Madhusmita
El-Rayes, Bassel F.
Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status
title Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status
title_full Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status
title_fullStr Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status
title_full_unstemmed Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status
title_short Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status
title_sort impact of tumor side on clinical outcomes in stage ii and iii colon cancer with known microsatellite instability status
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042136/
https://www.ncbi.nlm.nih.gov/pubmed/33859934
http://dx.doi.org/10.3389/fonc.2021.592351
work_keys_str_mv AT akcemehmet impactoftumorsideonclinicaloutcomesinstageiiandiiicoloncancerwithknownmicrosatelliteinstabilitystatus
AT zakkakaterina impactoftumorsideonclinicaloutcomesinstageiiandiiicoloncancerwithknownmicrosatelliteinstabilitystatus
AT jiangrenjian impactoftumorsideonclinicaloutcomesinstageiiandiiicoloncancerwithknownmicrosatelliteinstabilitystatus
AT williamsonshayla impactoftumorsideonclinicaloutcomesinstageiiandiiicoloncancerwithknownmicrosatelliteinstabilitystatus
AT aleseolatunjib impactoftumorsideonclinicaloutcomesinstageiiandiiicoloncancerwithknownmicrosatelliteinstabilitystatus
AT shaibwalidl impactoftumorsideonclinicaloutcomesinstageiiandiiicoloncancerwithknownmicrosatelliteinstabilitystatus
AT wuchristina impactoftumorsideonclinicaloutcomesinstageiiandiiicoloncancerwithknownmicrosatelliteinstabilitystatus
AT beheramadhusmita impactoftumorsideonclinicaloutcomesinstageiiandiiicoloncancerwithknownmicrosatelliteinstabilitystatus
AT elrayesbasself impactoftumorsideonclinicaloutcomesinstageiiandiiicoloncancerwithknownmicrosatelliteinstabilitystatus